Gb Sciences Inc. (GBLX)

Overview

GB Sciences, Inc. is a leading phytomedical research and biopharmaceutical drug development company that specializes in the discovery and development of plant-based medicines. With its state-of-the-art research facilities, the company focuses on pioneering cannabinoid-inspired medicines alongside complex therapeutic mixtures aimed at addressing a variety of medical conditions. Originally known as Growblox Sciences, Inc., the company underwent a name change to GB Sciences, Inc. in October 2016, signaling a broader focus in its scientific endeavors. Founded in 2001 and headquartered in Las Vegas, Nevada, GB Sciences stands at the forefront of integrating traditional botanical medicine with modern scientific approaches to drug development, concentrating on pre-clinical animal stages across a spectrum of therapeutic areas.

Products and Services

• Cannabinoid-Inspired Medicines

  At the core of GB Sciences' product portfolio are cannabinoid-inspired medicines designed to exploit the therapeutic potential of cannabinoids. These products are developed following meticulous research and are aimed at treating a vast range of pathologies with the precision and efficacy that synthetic cannabinoids offer. The company leverages its cannabinoid research to provide novel solutions in the pharmaceutical domain.

• Complex Therapeutic Mixtures

  Complementing its cannabinoid-based products, GB Sciences is also engaged in the development of complex therapeutic mixtures. These mixtures are founded on the understanding of plant-based medicine, intertwined with cutting-edge science to create highly effective prescription drugs. The aim is to address the needs of patients with specific health conditions that have been traditionally challenging to treat.

• Intellectual Property Portfolio

  GB Sciences' strong intellectual property portfolio encompasses a wide range of medical conditions. This includes but is not limited to programs in pre-clinical animal stage targeting Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular conditions. Each program is a testament to the company's commitment to advancing research and development in phytomedical science.